Lidds AB Logo

Lidds AB

Develops oncology drugs using a technology for local, controlled, and sustained drug release.

LIDDS | ST

Overview

Corporate Details

ISIN(s):
SE0001958612
LEI:
549300YYW8B918K7UN72
Country:
Sweden
Address:
Box 12040, 112 40 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lidds AB is a pharmaceutical company that develops oncology treatments based on its proprietary NanoZolid® drug delivery technology. The NanoZolid® platform enables local, controlled, and sustained release of drugs, aiming to increase therapeutic efficacy at the tumor site while reducing systemic side effects. The technology involves injecting a drug formulation that forms a solid depot, which releases the active substance over a prolonged period before being fully absorbed by the body. Lidds' pipeline includes projects such as Liproca Depot for prostate cancer, Nanodotax, and Nanoimod. The company's strategy focuses on reformulating existing drugs to lower development costs and enhance market potential. The technology is validated through clinical trials and strategic partnerships, including agreements with Johnson & Johnson Enterprise Innovation and Puheng Pharma.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lidds AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lidds AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lidds AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-02-14 Anders Månsson Other Buy 100,000 140,000.00 SEK
2023-02-10 Matthew Lindon Other Buy 71,428 99,999.20 SEK
2023-02-09 Daniel Lifveredson Other Other 150,000 210,000.00 SEK
2022-12-16 Daniel Lifveredson Other Sell 435,254 826,982.60 SEK
2022-12-16 Daniel Lifveredson Other Buy 435,254 826,982.60 SEK
2022-06-02 Galba Holding AB Other Buy 750,000 4,500,000.00 SEK
2022-03-08 Jan Törnell Other Buy 5,000 32,500.00 SEK
2021-06-30 Nina Herne Other Other 100,000 116,000.00 SEK
2021-06-03 Daniel Lifveredson Other Buy 435,254 4,483,116.20 SEK
2021-05-31 Maria Forss Other Buy 2,300 29,992.00 SEK

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.